Insulinoma is a rare form of tumour of the beta cells of pancreas resulting in an excessive secretion of insulin, leading to hypoglycaemia. Most insulinomas are benign, however a few metastasize. The symptoms of insulinoma are hypoglycaemia and associated symptoms such as blurred vision, lethargy, diplopia, light headedness, and convulsions, unconsciousness, which can also be life-threatening. Severe hypoglycemia may result in seizures, coma, and permanent neurological damage. Symptoms such as palpitations, tachycardia, sweating, hunger, anxiety etc. are caused by catecholaminergic response to hypoglycaemia triggered by insulinomas.

Insulinomas occur in people between the ages of 40 and 60 and grow slowly. The exact causes of insulinoma are unknown, however, patients with multiple endocrine neplasia type 1 syndrome or von Hippel-Landau syndrome are more at risk. According to a cancer research, 10% of insulinomas are cancerous and approximately 10% of patients diagnosed with insulinoma have more than one tumour. Insulinomas affect between up to five people out of one million each year.

Surgery is the definitive treatment for insulinomas and 90% of patients are cured of the condition. However, surgery can cause diabetes if significant amount of the pancreas are removed. The development of minimal invasive surgery procedures such as laparoscopy has resulted in replacement of open pancreatectomy which was once the gold standard of treatment. The market constraints are lack of awareness, misdiagnosis of the disease, risk of surgery, high cost of treatment etc.

The global insulinoma market is expected to reach USD 3.3 billion by 2023, and the market is projected to grow at a CAGR of ~ 3.3 % during the forecast period 2017-2023.
Intended Audience

- Global insulinoma treatment manufacturers & suppliers
- Research and development (R&D) companies
- Hospitals and clinics
- Academic institutes and universities

Figure 1  **Global insulinoma market by types, 2016 (%)**

Segments:
The global insulinoma market has been segmented on the basis of type, diagnosis, treatment, and end user.

Based on type, the market has been segmented as benign, and metastasize.

Based on diagnosis, the market has been segmented as blood test, endoscopic ultrasound,
Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and others. Based on treatment, the market has been segmented as surgery, drugs, radiofrequency ablation, chemotherapy and others. Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.

**Regional Analysis**
The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new products and surgical procedures in the US drives the insulinoma market. Also, concentration of major healthcare companies in the developed countries of this region coupled with the larger insurance penetration is adding fuel to the market growth. Moreover, the US expend high on the healthcare, which accounts for 16% of GDP also cruises the sale of insulinoma treatment.

Europe is the second largest market in the world due to high income and strong healthcare penetration. European market growth is led by countries such as Germany and France. The UK is expected to be the fastest growing market over the assessment period.

Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs during the forecast period. South East Asian countries such as Vietnam, Thailand, and Malaysia are projected to contribute highly to the market growth.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for will be Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development. However, Africa has the highest unmet needs in the world and cost-effective products will be the key to dominate the African market.

**Key Players in the Global Insulinoma Market**
One of key players profiled in the report are Abcam plc, cironpharma, Pfizer Plc., Entax Medical, Olympus, Boston Scientific Corporation, Medtronic, Cook Medical, Cook Medical, Inc., and others.
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
6. Global Insulinoma Market, by Types
6.1 Introduction
6.2 Benign
6.2.1 Market Estimates & Forecast, 2017-2023
6.3 Metastasize
6.3.1 Market Estimates & Forecast, 2017-2023
7. Global Insulinoma Market, by Diagnosis
7.1 Introduction
7.2 Blood Test
7.2.1 Market Estimates & Forecast, 2017-2023
7.3 Endoscopic Ultrasound
7.3.1 Market Estimates & Forecast, 2017-2023
7.4 Computed Tomography (CT)
7.4.1 Market Estimates & Forecast, 2017-2023
7.5 Magnetic Resonance Imaging (MRI)
7.5.1 Market Estimates & Forecast, 2017-2023
7.6 Others
7.6.1 Market Estimates & Forecast, 2017-2023
8. Global Insulinoma Market, by Treatment
8.1 Introduction
8.2 Surgery
8.2.1 Market Estimates & Forecast, 2017-2023
8.3 Drugs
8.3.1 Market Estimates & Forecast, 2017-2023
8.4 Radiofrequency Ablation
8.4.1 Market Estimates & Forecast, 2017-2023
8.5 Chemotherapy
8.5.1 Market Estimates & Forecast, 2017-2023
8.6 Other
8.6.1 Market Estimates & Forecast, 2017-2023
9. Global Insulinoma Market, by End User
9.1 Introduction
9.2 Hospitals & Clinics
9.2.1 Market Estimates & Forecast, 2017-2023
9.3 Academic and Research Institutes
9.3.1 Market Estimates & Forecast, 2017-2023
9.4 Others
9.4.1 Market Estimates & Forecast, 2017-2023
10. Global Insulinoma Market, by Region
10.1 Introduction
10.2 Americas
  10.2.1 North America
    10.2.1.1 US
    10.2.1.2 Canada
  10.2.2 South America
10.3 Europe
  10.3.1 Western Europe
    10.3.1.1 Germany
    10.3.1.2 France
    10.3.1.3 UK
    10.3.1.4 Italy
    10.3.1.5 Spain
    10.3.1.6 Rest of Western Europe
  10.3.2 Eastern Europe
10.4 Asia Pacific
  10.4.1 Japan
  10.4.2 China
  10.4.3 India
  10.4.4 Australia
  10.4.5 Republic of Korea
  10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
  10.5.1 United Arab Emirates
  10.5.2 Saudi Arabia
  10.5.3 Oman
  10.5.4 Kuwait
  10.5.5 Qatar
  10.5.6 Rest of the Middle East & Africa
11 Company Landscape
  11.1 Introduction
  11.2 Market Share Analysis
  11.3 Key Development & Strategies
    11.3.1 Key Developments
12 Company Profiles
  12.1 Abcam plc
    12.1.1 Overview
    12.1.2 Product Overview
    12.1.3 Financials
    12.1.4 Key Developments
  12.2 cironpharma
    12.2.1 Overview
    12.2.2 Product Overview
    12.2.3 Financials
    12.2.4 Key Developments
  12.3 Entax Medical
    12.3.1 Overview
    12.3.2 Product Overview
12.3.3 Financials
12.3.4 Key Development
12.4 Pfizer Plc.
12.4.1 Overview
12.4.2 Product Overview
12.4.3 Financials
12.4.4 Key Development
12.5 Olympus
12.5.1 Overview
12.5.2 Product Overview
12.5.3 Financials
12.5.4 Key Development
12.6 Medtronic
12.6.1 Overview
12.6.2 Product Overview
12.6.3 Financials
12.6.4 Key Development
12.7 Boston Scientific Corporation
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Development
12.8 Cook Medical
12.8.1 Overview
12.8.2 Product Overview
12.8.3 Financials
12.8.4 Key Development
12.9 Cook Medical, Inc.
12.9.1 Overview
12.9.2 Product Overview
12.9.3 Financials
12.9.4 Key Development
12.10 Others
12.10.1 Overview
12.10.2 Product Overview
12.10.3 Financials
12.10.4 Key Development

13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Pharmaceutical Industry

14 Appendix

List of Tables
TABLE 1 GLOBAL INSULINOMA MARKET, BY TYPE, 2017-2023 (USD MILLION)
TABLE 2 BENIGN FOR INSULINOMA MARKET, BY REGION, 2017-2023 (USD MILLION)
TABLE 3 METASTASIZE FOR INSULINOMA MARKET, BY REGION 2017-2023 (USD MILLION)
TABLE 4 GLOBAL INSULINOMA MARKET, BY DIAGNOSIS, 2017-2023 (USD MILLION)
TABLE 5 BLOOD TEST FOR INSULINOMA MARKET, BY REGION, 2017-2023 (USD MILLION)
TABLE 6 ENDOSCOPIC ULTRASOUND FOR INSULINOMA MARKET, BY REGION 2017-2023 (USD MILLION)
TABLE 7 COMPUTED TOMOGRAPHY (CT) FOR INSULINOMA MARKET, BY REGION 2017-2023 (USD MILLION)
TABLE 8 MAGNETIC RESONANCE IMAGING (MRI) FOR INSULINOMA MARKET, BY REGION 2017-2023 (USD MILLION)
TABLE 9 OTHERS FOR INSULINOMA MARKET, BY REGION 2017-2023 (USD MILLION)
TABLE 10 GLOBAL INSULINOMA MARKET, BY TREATMENT, 2017-2023 (USD MILLION)
TABLE 11 SURGERY FOR INSULINOMA MARKET, BY REGION 2017-2023 (USD MILLION)
TABLE 12 DRUGS FOR INSULINOMA MARKET, BY REGION 2017-2023 (USD MILLION)
TABLE 13 RADIOFREQUENCY ABLATION FOR INSULINOMA MARKET, BY REGION 2017-2023 (USD MILLION)
TABLE 14 CHEMOTHERAPY FOR INSULINOMA MARKET, BY REGION 2017-2023 (USD MILLION)
TABLE 15 OTHERS FOR INSULINOMA MARKET, BY REGION 2017-2023 (USD MILLION)
TABLE 16 GLOBAL INSULINOMA MARKET, BY END USER, 2017-2023 (USD MILLION)
TABLE 17 NORTH AMERICA INSULINOMA MARKET, BY COUNTRY 2017-2023 (USD MILLION)
TABLE 18 NORTH AMERICA INSULINOMA MARKET, BY TYPE 2017-2023 (USD MILLION)
TABLE 19 NORTH AMERICA INSULINOMA MARKET, BY DIAGNOSIS 2017-2023 (USD MILLION)
TABLE 20 NORTH AMERICA INSULINOMA MARKET, BY TREATMENT 2017-2023 (USD MILLION)
TABLE 21 NORTH AMERICA INSULINOMA MARKET, BY END USER, 2017-2023 (USD MILLION)
TABLE 22 NORTH AMERICA INSULINOMA MARKET BY REGION 2017-2023 (USD MILLION)
TABLE 23 EUROPE INSULINOMA MARKET BY COUNTRY 2017-2023 (USD MILLION)
TABLE 24 EUROPE INSULINOMA MARKET, BY TYPE 2017-2023 (USD MILLION)
TABLE 25 EUROPE INSULINOMA MARKET, BY DIAGNOSIS 2017-2023 (USD MILLION)
TABLE 26 EUROPE INSULINOMA MARKET, BY TREATMENT 2017-2023 (USD MILLION)
TABLE 27 EUROPE INSULINOMA MARKET, BY END USER, 2017-2023 (USD MILLION)
TABLE 28 EUROPE INSULINOMA MARKET, BY REGION 2017-2023 (USD MILLION)
TABLE 29 ASIA PACIFIC INSULINOMA MARKET BY COUNTRY 2017-2023 (USD MILLION)
TABLE 30 ASIA PACIFIC INSULINOMA MARKET, BY TYPE 2017-2023 (USD MILLION)
TABLE 31 ASIA PACIFIC INSULINOMA MARKET, BY DIAGNOSIS 2017-2023 (USD MILLION)
TABLE 32 ASIA PACIFIC INSULINOMA MARKET, BY TREATMENT 2017-2023 (USD MILLION)
TABLE 33 ASIA PACIFIC INSULINOMA MARKET, BY END USER, 2017-2023 (USD MILLION)
TABLE 34 ASIA PACIFIC INSULINOMA MARKET, BY REGION 2017-2023 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA INSULINOMA MARKET, BY REGION 2017-2023 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA INSULINOMA MARKET BY COUNTRY 2017-2023 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA INSULINOMA MARKET, BY TYPE 2017-2023 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA INSULINOMA MARKET, BY DIAGNOSIS 2017-2023 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA INSULINOMA MARKET, BY TREATMENT 2017-2023 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA INSULINOMA MARKET, BY END USER, 2017-2023 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA INSULINOMA MARKET, BY REGION 2017-2023 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET DYNAMICS FOR GLOBAL INSULINOMA MARKET
FIGURE 3 GLOBAL INSULINOMA MARKET, BY SEGMENT, 2016